About ARISE

ARISE II: ICH, CVD, and ICAD Roundtable Discussion with Industry and Stroke Experts

Stroke is a leading cause of death and serious long-term disability worldwide, with an estimated global prevalence of over 104.2 million people. With about 6.2 million deaths attributed to cerebrovascular diseases annually, ischemic and hemorrhagic strokes remain major threats to public health. There is no indication that these numbers changed significantly despite advances in modification of risk factors and specific preventive treatment of some etiologic factors. One major challenge is the highly heterogenous nature of potential causes of stroke, which require a concerted multidisciplinary approach to design and conduct of clinical prevention trials. Albeit well-designed successful clinical trials have led to significant advancement of management of stroke victims, there is the need for improvement and conduct. Newer data on the epidemiology of these diseases and innovative solutions must be integrated in the management of these patients through better collaboration among the major stakeholders: academia, government-based funding and regulatory organizations, and industry.

Our mission

The ARISE Consensus Conferences, via a collaboration of medical academia, the healthcare industry and government agencies, are intended to advance and accelerate research in the treatment of intracranial hemorrhage (ICH), intracranial atherosclerotic disease (ICAD), and cerebral venous diseases (CVD), to ultimately result in improved acute and elective management, treatment, and prevention. To achieve this goal,

ARISE 2024 will:

- *Develop new approaches to overcome barriers impeding drug and device development*
- *Identify, clarify, and communicate the implications of new research for cerebrovascular diseases*
- *Publish the consensus recommendations of ARISE participants which address these concerns*
- *Promote adoption of ARISE solutions by research, industry, clinical and government communities*

Who is involved

ARISE architecture thus includes 3 major stakeholders research and practice in the treatment of cerebrovascular disease: academia (leading international physicians/scientists from all involved disciplines), industry (scientists and executives from private sector pharmaceutical, device, and imaging companies), and regulatory institutions (executive managers, physicians and scientists from NIH and FDA).

Preliminary Agenda:

ARISE starts with a one full day meeting focusing on cutting-edge clinical and research study designs, analytic methods, novel drugs/devices, biomarkers, and outcomes. The specific sessions included in the program are:

- SESSION 1: Intracerebral hemorrhage (ICH) – NEW DATA, NEW LANDSCAPE, NEW APROACHES
- SESSION 2: Cerebral Venous Diseases: NEW DATA, NEW LANDSCAPE, NEW APROACHES
- SESSION 3: Intracranial Atherocclusive Disease (ICAD): NEW DATA, NEW LANDSCAPE, NEW APROACHES
- SESSION 4: REGULATORY PERSPECTIVE ON KEY CLINICAL TRIAL ISSUES

The second day of the ARISE is focused on the consensus process to develop recommendations. Participating experts from

academia, industry and regulatory institutions are divided into 3 groups for preparation of the consensus recommendations. They are provided equal opportunity to contribute to a facilitated discussion process, during which recommendations developed by leading academic thought leaders in ICH, ICAD, and CVD are presented, openly discussed, and may be amended, expanded, replaced, and refined by the group. Each of the 3 content groups then present their recommendations to the entire assembly. Writing committees draft the manuscripts for review of the group and the resulting articles are then published.

Funding

ARISE does not receive any government funding. The ARISE Roundtable is funded solely by participating private sector companies.